利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.037 秒)

    Modulation of Cell Barrier Dysfunction
    1.
    发明申请
    Modulation of Cell Barrier Dysfunction 审中-公开
    细胞屏障功能障碍的调节

    公开(公告)号：US20080194611A1

    公开(公告)日：2008-08-14

    申请号：US11914984

    申请日：2006-05-06

    申请人： John C. Alverdy ,  Jonathan Moss ,  Mark W. Lingen ,  Patrick A. Singleton ,  Joe G.N. Garcia

    发明人： John C. Alverdy ,  Jonathan Moss ,  Mark W. Lingen ,  Patrick A. Singleton ,  Joe G.N. Garcia

    IPC分类号： A61K31/485 ,  A61K31/445 ,  A61P31/00 ,  A61P17/00

    CPC分类号： A61K31/485 ,  A61K31/445

    摘要： The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders. The diseases or disorders may amenable to the methods include inflammation, such as acute lung injury, atherosclerosis, gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly (pig-bel), Pseudomonas-mediated opthalmologic infection, Pseudomonas-mediated otologic infection and Pseudomonas-mediated cutaneous infection. More generally, epithelial cell barrier disorders are contemplated as amenable to the prophylactic and therapeutic methods. The diseases and disorders may be induced by microbial pathogens, including bacterial pathogens such as Pseudomonas aeruginosa. The invention further provides prophylactic and therapeutic methods for inhibiting the expression of bacterial PA-I lectin/adhesin and for inhibiting bacterial MvfR activity levels. Also provided is a method of using a μ-opioid receptor antagonist in the manufacture of a medicament for use in the methods described herein.

    摘要翻译： 本发明提供了用于施用μ-阿片样物质受体拮抗剂以治疗细胞屏障疾病和病症如内皮细胞和上皮细胞屏障疾病和病症的预防和治疗方法。 疾病或病症可适用于该方法，包括炎症，例如急性肺损伤，动脉粥样硬化，肠源性败血症，烧伤，新生儿坏死性小肠结肠炎，严重中性粒细胞减少症，中毒性结肠炎，炎性肠病，肠病，移植排斥反应，肠炎， 猪肚（猪皮），假单胞菌介导的眼科感染，假单胞菌介导的耳科感染和假单胞菌介导的皮肤感染。 更一般地，预期上皮细胞屏障障碍可用于预防和治疗方法。 疾病和病症可能由微生物病原体引起，包括细菌性病原体如铜绿假单胞菌（Pseudomonas aeruginosa）。 本发明还提供了用于抑制细菌PA-1凝集素/粘附素表达和抑制细菌MvfR活性水平的预防和治疗方法。 还提供了在制备用于本文所述方法中的药物中使用μ-阿片受体拮抗剂的方法。

    Modulation of Cell Barrier Dysfunction
    2.
    发明申请
    Modulation of Cell Barrier Dysfunction 审中-公开
    细胞屏障功能障碍的调节

    公开(公告)号：US20120316190A1

    公开(公告)日：2012-12-13

    申请号：US13483932

    申请日：2012-05-30

    申请人： John C. Alverdy ,  Jonathan Moss ,  Mark W. Lingen ,  Patrick A. Singleton ,  Joe G.N. Garcia

    发明人： John C. Alverdy ,  Jonathan Moss ,  Mark W. Lingen ,  Patrick A. Singleton ,  Joe G.N. Garcia

    IPC分类号： A61K31/485 ,  A61P1/00

    CPC分类号： A61K31/485 ,  A61K31/445

    摘要： The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist, e.g., N-methylnaltrexone or a salt thereof, to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders, e.g., inflammatory bowel disease. Methods of reducing the symptoms of inflammatory bowel disease and the risk of developing inflammatory bowel disease are also provided.

    摘要翻译： 本发明提供了用于施用μ-阿片受体拮抗剂（例如N-甲基纳曲酮或其盐）以治疗细胞屏障疾病和病症（例如内皮和上皮细胞屏障疾病和病症，例如炎症性肠病）的预防和治疗方法 。 还提供了减少炎症性肠病的症状和发展为炎性肠病的风险的方法。

    Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds
    5.
    发明申请
    Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds 审中-公开
    通过管理高分子量PEG样化合物治疗内皮和上皮细胞疾病的方法

    公开(公告)号：US20090186949A1

    公开(公告)日：2009-07-23

    申请号：US12281102

    申请日：2007-02-28

    申请人： John C. Alverdy ,  Joe G.N. Garcia ,  Steven Dudek

    发明人： John C. Alverdy ,  Joe G.N. Garcia ,  Steven Dudek

    IPC分类号： A61K31/08 ,  A61P11/00

    CPC分类号： A61K31/765

    摘要： The invention provides methods of screening for modulators of microbial PA-I lectin/adhesin activity, including modulators of PA-I expression, as well as the modulators so identified, pharmaceutical compositions and kits containing such modulators. These modulators include soluble and membrane-bound bacterial signaling compounds produced by cells of a host containing a microbial pathogen. Methods for preventing and treating cell disorders, such as epithelial cell disorders including gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly, Pseudomonas-mediated opthalmologic infection, Pseudomonas-mediated otologic infection and Pseudomonas-mediated cutaneous infection, using the modulators are contemplated, as are methods for ameliorating a symptom associated with such a disorder. The invention further provides methods of treating or preventing disorders of the lung, including disorders affecting endothelial or epithelial cell barrier function, such as acute respiratory distress syndrome or pulmonary edema, as well as methods of preventing such disorders, and the above-named disorders, such as neonatal necrotizing enterocolitis, by administering a high molecular weight polyethylene glycol-like compound. Related methods of ameliorating a symptom associated with one of these disorders is also contemplated.

    摘要翻译： 本发明提供筛选微生物PA-1凝集素/粘附素活性的调节剂的方法，包括PA-1表达的调节剂，以及如此鉴定的调节剂，含有这种调节剂的药物组合物和试剂盒。 这些调节剂包括由含有微生物病原体的宿主的细胞产生的可溶性和膜结合的细菌信号化合物。 用于预防和治疗细胞病症的方法，例如包括肠源性败血症，烧伤，新生儿坏死性小肠结肠炎，严重中性粒细胞减少症，中毒性结肠炎，炎性肠病，肠病，移植排斥反应，肠胃炎，猪肚，假单胞菌介导的上皮细胞病症 预期使用调节剂的眼科感染，假单胞菌素介导的耳科感染和假单胞菌素介导的皮肤感染，以及用于改善与这种病症相关的症状的方法。 本发明进一步提供了治疗或预防肺疾病的方法，包括影响内皮细胞或上皮细胞屏障功能的疾病，例如急性呼吸窘迫综合征或肺水肿，以及预防这种疾病的方法，以及上述疾病， 例如新生儿坏死性小肠结肠炎，通过施用高分子量聚乙二醇样化合物。 还考虑了改善与这些疾病之一相关的症状的相关方法。

    METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS INVOLVING HIGHER MOLECULAR WEIGHT HYALURONAN
    6.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS INVOLVING HIGHER MOLECULAR WEIGHT HYALURONAN 审中-公开
    治疗涉及高分子量羟尿酸的疾病和病症的方法和组合物

    公开(公告)号：US20100249064A1

    公开(公告)日：2010-09-30

    申请号：US12676793

    申请日：2008-09-05

    申请人： Patrick A. Singleton ,  Joe G.N. Garcia

    发明人： Patrick A. Singleton ,  Joe G.N. Garcia

    IPC分类号： A61K31/7008 ,  A61P9/10 ,  A61P9/00

    CPC分类号： A61K31/17 ,  A61K31/728

    摘要： The present invention concerns methods and compositions involving hyaluronan that has been substantially purified to enrich for hyaluronan with a molecular weight above 500 kilodaltons. This hyaluronan can be used for diseases and conditions characterized or caused by increased vascular permeability or angiogenesis. The higher molecular weight hyaluronan restores vascular integrity and inhibits angiogenesis in embodiments of the invention.

    摘要翻译： 本发明涉及涉及透明质酸的方法和组合物，该方法和组合物已被基本纯化以富集分子量高于500千道尔顿的透明质酸。 该透明质酸可用于由血管通透性增加或血管生成增加而引起的疾病和病症。 更高分子量的透明质酸在本发明的实施方案中恢复血管完整性并抑制血管生成。

    Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists
    7.
    发明申请
    Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists 审中-公开
    使用鞘氨醇1磷酸酯类似物或鞘磷脂1磷酸酯受体激动剂治疗急性肺损伤的方法

    公开(公告)号：US20130079309A1

    公开(公告)日：2013-03-28

    申请号：US13582627

    申请日：2011-03-03

    申请人： Joe G.N. Garcia ,  Steven M. Dudek

    发明人： Joe G.N. Garcia ,  Steven M. Dudek

    IPC分类号： A61K31/662 ,  A61K31/4245 ,  A61K31/137

    CPC分类号： A61K31/662 ,  A61K31/137 ,  A61K31/4245 ,  G01N33/92 ,  G01N2405/08 ,  G01N2800/40

    摘要： The invention provides methods for treating or reducing the risk of developing acute lung injury manifested by increased vascular permeability. Also provided are pharmaceutical compositions comprising an FTY720 analog or derivative and/or SEW 2871 for use in the disclosed methods. The invention also provides methods for treating or reducing the risk of developing acute lung injury resulting from dysregulation of ceramide/sphingolipid pathway, more specifically, acute lung injury resulting from radiation.

    摘要翻译： 本发明提供了治疗或降低由血管通透性增加所表现的急性肺损伤风险的方法。 还提供了包含用于所公开的方法的FTY720类似物或衍生物和/或SEW2871的药物组合物。 本发明还提供了用于治疗或降低由神经酰胺/神经鞘脂途径失调引起的急性肺损伤的风险的方法，更具体地说，是由放射引起的急性肺损伤。

    NITRATED SPHINGOSINE 1-PHOSPHATE 3 RECEPTOR AS A PREDICTOR OF ACUTE LUNG INJURY-ASSOCIATED MORTALITY
    9.
    发明申请
    NITRATED SPHINGOSINE 1-PHOSPHATE 3 RECEPTOR AS A PREDICTOR OF ACUTE LUNG INJURY-ASSOCIATED MORTALITY 审中-公开
    硝酸磷脂酸1-磷酸3受体作为急性肺损伤相关的死亡原因

    公开(公告)号：US20140323545A1

    公开(公告)日：2014-10-30

    申请号：US14236901

    申请日：2012-08-06

    申请人： Joe G.N. Garcia

    发明人： Joe G.N. Garcia

    IPC分类号： G01N33/53

    CPC分类号： G01N33/53 ,  G01N33/566 ,  G01N2333/726 ,  G01N2800/125 ,  G01N2800/26

    摘要： The disclosure relates to a method of determining risk of mortality from Acute Lung Injury (ALI), sepsis, or a combination thereof in a patient, as well as a method of diagnosing ALI in a patient with sepsis based on the presence of tyrosine-nitrated sphingosine 1-phosphate 3 receptor (S1P3R) protein. The disclosure additionally relates to a method of treating an Acute Lung Injury (ALI) patient with sepsis based on the presence of tyrosine-nitrated S1P3R protein.

    摘要翻译： 本公开涉及一种确定患者的急性肺损伤（ALI），败血症或其组合的死亡风险的方法，以及基于存在酪氨酸 - 硝化细胞的败血症患者的ALI诊断方法 鞘氨醇1-磷酸3受体（S1P3R）蛋白。 本公开另外涉及基于酪氨酸 - 硝化的S1P3R蛋白的存在来治疗患有败血症的急性肺损伤（ALI）患者的方法。

    METHODS AND COMPOSITIONS INVOLVING PBEF INHIBITORS FOR LUNG INFLAMMATION CONDITIONS AND DISEASES
    10.
    发明申请
    METHODS AND COMPOSITIONS INVOLVING PBEF INHIBITORS FOR LUNG INFLAMMATION CONDITIONS AND DISEASES 有权
    涉及肺损伤条件和疾病的PBEF抑制剂的方法和组合物

    公开(公告)号：US20110020364A1

    公开(公告)日：2011-01-27

    申请号：US12842773

    申请日：2010-07-23

    申请人： Joe G.N. Garcia

    发明人： Joe G.N. Garcia

    IPC分类号： A61K39/395 ,  A61K38/02 ,  A61K31/7088 ,  A61P11/00

    CPC分类号： C07K16/243 ,  A61K2039/505 ,  C07K2317/76 ,  C12N15/1136 ,  C12N2310/14

    摘要： The present invention concerns methods and compositions involving inhibitors of Pre-B Cell Colony Enhancing Factor (PBEF) for inflammatory conditions and diseases, including acute lung injury (ALI), ventilator-induced lung injury (VILI), and acute respiratory distress syndrome (ARDS). The present invention also concerns biomarkers for inflammation as well as methods for screening for PBEF inhibitors.

    摘要翻译： 本发明涉及涉及用于炎性病症和疾病的前B细胞集落增强因子（PBEF）抑制剂的方法和组合物，包括急性肺损伤（ALI），呼吸机诱发的肺损伤（VILI）和急性呼吸窘迫综合征（ARDS） ）。 本发明还涉及用于炎症的生物标志物以及用于筛选PBEF抑制剂的方法。